Therapeutic window of dopamine D2/3 receptor occupancy to treat psychosis in Alzheimer's disease

Brain

Volumn 140, Issue 4, 2017, Pages 1117-1127

  Reeves, Suzanne ^a,b   McLachlan, Emma ^b   Bertrand, Julie ^a,c   Antonio, Fabrizia D ^a,b   Brownings, Stuart ^a   Nair, Akshay ^a   Greaves, Suki ^d   Smith, Alan ^d   Taylor, David ^d   Dunn, Joel ^e   Marsden, Paul ^e   Kessler, Robert ^f   Howard, Robert ^a,b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITÉ PARIS DIDEROT   (France)

^d SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^e ST THOMAS HOSPITAL   (United Kingdom)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

18F fallypride; Alzheimer's; amisulpride; D2 3 occupancy; psychosis

Indexed keywords

AMISULPRIDE; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; FALLYPRIDE F 18; FLUORINE 18; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; DOPAMINE RECEPTOR STIMULATING AGENT; N-((1-ALLYL-2-PYRROLIDINYL)METHYL)-5-(3-FLUOROPROPYL)-2,3-DIMETHOXYBENZAMIDE; NEUROLEPTIC AGENT; PYRROLIDINE DERIVATIVE; SULPIRIDE; SULTOPRIDE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BLOOD SAMPLING; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL OUTCOME; CONTROLLED STUDY; DELUSION; DRUG BLOOD LEVEL; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HALLUCINATION; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; PUTAMEN; RECEPTOR OCCUPANCY; SCHIZOPHRENIA; THALAMUS; THERAPEUTIC INDEX; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECTS; PHASE 1 CLINICAL TRIAL; PSYCHOLOGY; PSYCHOTIC DISORDERS; SOCIOECONOMICS; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZAMIDES; DOPAMINE AGENTS; FEMALE; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PSYCHOTIC DISORDERS; PYRROLIDINES; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3; SOCIOECONOMIC FACTORS; SULPIRIDE; TREATMENT OUTCOME;

EID: 85017835212     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww359     Document Type: Article

References (62)

1. Assawasuwannakit P, Braund R, Duffull SB. A framework for quantifying the influence of adherence and dose individualization. Clin Pharmacol Ther 2016; 99: 452-9.
2. Bigos KL, Pollock BG, Coley KC, Miller del D, Marder SR, Aravagiri M, et al. Sex, race, and smoking impact olanzapine exposure. J Clin Pharmacol 2008; 48: 157-65.
3. Blaschke TF, Osterberg L, Vrijens B, Urquhart J. Adherence to medications: insights arising from studies on the unreliable link between prescribed and actual drug dosing histories. Annu Rev Pharmacol Toxicol 2012; 52: 275-301.
4. Bressan RA, Erlandsson K, Jones HM, Mulligan R, Flanagan RJ, Ell PJ, et al. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients. Am J Psychiatry 2003; 160: 1413-20.
5. Clark-Papasavas C, Dunn JT, Greaves S, Mogg A, Gomes R, Brownings S, et al. Towards a therapeutic window of D2/3 occupancy for treatment of psychosis in Alzheimer's disease, with [18F]fallypride positron emission tomography. Int J Geriatr Psychiatry 2014; 29: 1001-9.
6. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
7. Dos Santos Pereira JN, Tadjerpisheh S, Abu Abed M, Saadatmand AR, Weksler B, Romero IA, et al. The poorly membrane permeable antipsychotic drugs amisulpride and sulpiride are substrates of the organic cation transporters from the SLC22 family. AAPS J 2014; 16: 1247-58.
8. Dunn JT, Clark-Papasavas C, Marsden P, Baker S, Cleij M, Kapur S, et al. Establishing test-retest reliability of an adapted [(18)F]fallypride imaging protocol in older people. J Cereb Blood Flow Metab 2013; 33: 1098-103.
9. Ette EI, Williams PJ, Lane JR. Population pharmacokinetics III: design, analysis, and application of population pharmacokinetic Studies. Ann Pharmacother 2004; 38: 2136-44.
10. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G. Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 1992; 49: 538-44.
11. Feng Y, Pollock BG, Coley K, Marder S, Miller D, Kirshner M, et al. Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study. Br J Clin Pharmacol 2008; 66: 629-39.
12. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
13. Graff-Guerrero A, Rajji TK, Mulsant BH, Nakajima S, Caravaggio F, Suzuki T, et al. Evaluation of antipsychotic dose reduction in latelife Schizophrenia: a prospective dopamine D2/3 receptor occupancy study. JAMA Psychiatry 2015; 72: 927-34.
14. Hamon-Vilcot B, Chaufour S, Deschamps C, Canal M, Zieleniuk I, Ahtoy P, et al. Safety and pharmacokinetics of a single oral dose of amisulpride in healthy elderly volunteers. Eur J Clin Pharmacol 1998; 54: 405-9.
15. Hiemke C, Baumann P, Bergemann N, Conca A, Dietmaier O, Egberts K, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry 2011; 44: 195-235.
16. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
17. Jankowska-Polanska B, Katarzyna L, Lidia A, Joanna J, Dudek K, Izabella U. Cognitive function and adherence to anticoagulation treatment in patients with atrial fibrillation. J Geriatr Cardiol 2016; 13: 559-65.
18. Jennum P, Baandrup L, Ibsen R, Kjellberg J. Increased all-cause mortality with use of psychotropic medication in dementia patients and controls: a population-based register study. Eur Neuropsychopharmacol 2015; 25: 1906-13.
19. Jeste DV, Blazer D, Casey D, Meeks T, Salzman C, Schneider L, et al. ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia. Neuropsychopharmacology 2008; 33: 957-70.
20. Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sci 1995; 57: PL103-7.
21. Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, et al. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology 2008; 33: 3111-25.
22. Kessler RM, Ansari MS, Riccardi P, Li R, Jayathilake K, Dawant B, et al. Occupancy of striatal and extrastriatal dopamine D2 receptors by clozapine and quetiapine. Neuropsychopharmacology 2006; 31: 1991-2001.
23. Kim E, Howes OD, Yu KS, Jeong JM, Lee JS, Jang IJ, et al. Calculating occupancy when one does not have baseline: a comparison of different options. J Cereb Blood Flow Metab 2011; 31: 1760-7.
24. la Fougere C, Meisenzahl E, Schmitt G, Stauss J, Frodl T, Tatsch K, et al. D2 receptor occupancy during high-and low-dose therapy with the atypical antipsychotic amisulpride: a 123I-iodobenzamide SPECT study. J Nucl Med 2005; 46: 1028-33.
25. Lako IM, van den Heuvel ER, Knegtering H, Bruggeman R, Taxis K. Estimating dopamine D(2) receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol 2013; 33: 675-81.
26. Lammertsma AA, Hume SP. Simplified reference tissue model for PET receptor studies. Neuroimage 1996; 4 (3 Pt 1): 153-8.
27. Martinot JL, Paillere-Martinot ML, Poirier MF, Dao-Castellana MH, Loc'h C, Maziere B. In vivo characteristics of dopamine D2 receptor occupancy by amisulpride in schizophrenia. Psychopharmacology 1996; 124: 154-8.
28. Maust DT, Kim HM, Seyfried LS, Chiang C, Kavanagh J, Schneider LS, et al. Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm. JAMA Psychiatry 2015; 72: 438-45.
29. McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 1996; 47: 1113-24.
30. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34: 939-44.
31. Meisenzahl EM, Schmitt G, Grunder G, Dresel S, Frodl T, la Fougere C, et al. Striatal D2/D3 receptor occupancy, clinical response and side effects with amisulpride: an iodine-123-iodobenzamide SPET study. Pharmacopsychiatry 2008; 41: 169-75.
32. Morris ED, Chefer SI, Lane MA, Muzic RF Jr, Wong DF, Dannals RF, et al. Loss of D2 receptor binding with age in rhesus monkeys: importance of correction for differences in striatal size. J Cereb Blood Flow Metab 1999; 19: 218-29.
33. Mukherjee J, Yang ZY, Brown T, Roemer J, Cooper M. 18F-desmethoxyfallypride: a fluorine-18 labeled radiotracer with properties similar to carbon-11 raclopride for PET imaging studies of dopamine D2 receptors. Life Sci 1996; 59: 669-78.
34. Natesan S, Reckless GE, Barlow KB, Nobrega JN, Kapur S. Amisulpride the 'atypical' atypical antipsychotic-comparison to haloperidol, risperidone and clozapine. Schizophr Res 2008; 105: 224-35.
35. Olsson H, Farde L. Potentials and pitfalls using high affinity radioligands in PET and SPET determinations on regional drug induced D2 receptor occupancy - a simulation study based on experimental data. Neuroimage 2001; 14: 936-45.
36. Pretorius RW, Gataric G, Swedlund SK, Miller JR. Reducing the risk of adverse drug events in older adults. Am Fam Physician 2013; 87: 331-6.
37. Reeves S, Bertrand J, D'Antonio F, McLachlan E, Nair A, Brownings S, et al. A population approach to characterise amisulpride pharmacokinetics in older people and Alzheimer's disease. Psychopharmacology 2016; 233: 3371-81.
38. Reeves S, Brown R, Matthews D, Howard R, Grasby P. No effect of donepezil on striatal dopamine release in mild to moderate Alzheimer's disease. J Neurol Neurosurg Psychiatry 2010; 81: 119-21.
39. Schmitt U, Kirschbaum KM, Poller B, Kusch-Poddar M, Drewe J, Hiemke C, et al. In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. Pharmacol Biochem Behav 2012; 102: 312-20.
40. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail MS, et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355: 1525-38.
41. Seeman P. All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2(high) receptors. CNS Neurosci Ther 2011; 17: 118-32.
42. Seeman P. Therapeutic occupation of dopamine D2 antipsychotic receptors in Alzheimer's disease. Int J Geriatr Psychiatry 2014; 29: 1096.
43. Seeman P, Van Tol HH. Deriving the therapeutic concentrations for clozapine and haloperidol: the apparent dissociation constant of a neuroleptic at the dopamine D2 or D4 receptor varies with the affinity of the competing radioligand. Eur J Pharmacol 1995; 291: 59-66.
44. Sekhar G, Reeves S, Thomas S. Exploring the interaction of amisulpride with influx and efflux transporters expressed at the bloodbrain barrier. Proc Br Pharmacol Soc Abstract 2016; 13: 173P.
45. Sekine M, Maeda J, Shimada H, Nogami T, Arakawa R, Takano H, et al. Central nervous system drug evaluation using positron emission tomography. Clin Psychopharmacol Neurosci 2011; 9: 9-16.
46. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11-19.
47. Sparshatt A, Taylor D, Patel MX, Kapur S. Amisulpride - dose, plasma concentration, occupancy and response: implications for therapeutic drug monitoring. Acta Psychiatr Scand 2009; 120: 416-28.
48. Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/ D3 receptors are a common site of action for antipsychotic drugs - an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009; 35: 789-97.
49. Takano A, Suhara T, Ikoma Y, Yasuno F, Maeda J, Ichimiya T, et al. Estimation of the time-course of dopamine D2 receptor occupancy in living human brain from plasma pharmacokinetics of antipsychotics. Int J Neuropsychopharmacol 2004; 7: 19-26.
50. Tauscher J, Jones C, Remington G, Zipursky RB, Kapur S. Significant dissociation of brain and plasma kinetics with antipsychotics. Mol Psychiatry 2002; 7: 317-21.
51. Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson M, et al. Imaging dopamine receptors in humans with [11C]-( + )-PHNO: dissection of D3 signal and anatomy. Neuroimage 2011; 54: 264-77.
52. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, Crivello F, Etard O, Delcroix N, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. Neuroimage 2002; 15: 273-89.
53. Uchida H, Kapur S, Mulsant BH, Graff-Guerrero A, Pollock BG, Mamo DC. Sensitivity of older patients to antipsychotic motor side effects: a PET study examining potential mechanisms. Am J Geriatr Psychiatry 2009a; 17: 255-63.
54. Uchida H, Mamo DC, Mulsant BH, Pollock BG, Kapur S. Increased antipsychotic sensitivity in elderly patients: evidence and mechanisms. J Clin Psychiatry 2009b; 70: 397-405.
55. Uchida H, Suzuki T, Graff-Guerrero A, Mulsant BH, Pollock BG, Arenovich T, et al. Therapeutic window for striatal dopamine D(2/3) receptor occupancy in older patients with schizophrenia: a pilot PET study. Am J Geriatr Psychiatry 2014; 22: 1007-16.
56. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol 2011; 31: 497-502.
57. Urquhart J. The electronic medication event monitor. Lessons for pharmacotherapy. Clin Pharmacokinet 1997; 32: 345-56.
58. Vernaleken I, Peters L, Raptis M, Lin R, Buchholz HG, Zhou Y, et al. The applicability of SRTM in [(18)F]fallypride PET investigations: impact of scan durations. J Cereb Blood Flow Metab 2011; 31: 1958-66.
59. Vernaleken I, Siessmeier T, Buchholz HG, Hartter S, Hiemke C, Stoeter P, et al. High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. Int J Neuropsychopharmacol 2004; 7: 421-30.
60. Volkow ND, Wang GJ, Fowler JS, Logan J, Schlyer D, Hitzemann R, et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994; 16: 255-62.
61. Xiberas X, Martinot JL, Mallet L, Artiges E, Canal M, Loc'h C, et al. In vivo extrastriatal and striatal D2 dopamine receptor blockade by amisulpride in schizophrenia. J Clin Psychopharmacol 2001; 21: 207-14.
62. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc 2010; 58: 1749-57.